Akari Therapeutics (AKTX) Projected to Post Quarterly Earnings on Wednesday

Akari Therapeutics (NASDAQ:AKTX) is expected to post its Q1 2026 results after the market closes on Wednesday, May 20th. Analysts expect the company to announce earnings of ($1.33) per share for the quarter. Investors can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Tuesday, May 19, 2026 at 7:00 AM ET.

Akari Therapeutics (NASDAQ:AKTX) last released its earnings results on Monday, March 30th. The biopharmaceutical company reported ($2.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.03) by ($2.65).

Akari Therapeutics Trading Up 3.1%

Shares of NASDAQ:AKTX traded up $0.11 during midday trading on Tuesday, hitting $3.61. The company’s stock had a trading volume of 26,300 shares, compared to its average volume of 25,173. The stock’s 50 day simple moving average is $5.73 and its 200 day simple moving average is $11.07. Akari Therapeutics has a fifty-two week low of $3.02 and a fifty-two week high of $56.80.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on AKTX. Maxim Group lowered shares of Akari Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, April 8th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Akari Therapeutics in a research report on Monday, April 20th. Finally, HC Wainwright lifted their target price on shares of Akari Therapeutics to $27.00 and gave the company a “buy” rating in a research report on Wednesday, April 1st. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Akari Therapeutics currently has an average rating of “Hold” and an average target price of $89.00.

Institutional Investors Weigh In On Akari Therapeutics

A hedge fund recently bought a new stake in Akari Therapeutics stock. Armistice Capital LLC acquired a new position in shares of Akari Therapeutics PLC (NASDAQ:AKTX) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 2,723,966 shares of the biopharmaceutical company’s stock, valued at approximately $787,000. Armistice Capital LLC owned approximately 5.95% of Akari Therapeutics as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 5.06% of the company’s stock.

About Akari Therapeutics

Akari Therapeutics plc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel complement inhibitors for the treatment of inflammatory and immunological diseases. The company’s research centers on modulation of the complement cascade, a key component of the innate immune system, with the goal of delivering targeted therapies to patients suffering from rare and severe disorders.

Akari’s lead pipeline asset is sutimlimab, a humanized monoclonal antibody that selectively inhibits the C1s protein and is being evaluated in pivotal clinical studies for cold agglutinin disease.